CDMO Curia is to collaborate with Corning’s Advanced-Flow Reactor (AFR) team to expand and accelerate continuous flow development and manufacturing for the chemical and biopharmaceutical industries.  This includes installing Corning’s G1 production system (pictured), designed for the continuous industrial production of APIs at Curia’s Albany facility.

Curia has announced plans to invest about $35 million in order to expand commercial-scale API manufacturing capacity at its largest site in Rensselaer, New York, over the course of 18 months. This is the third significant announcement in the month since the former AMRI renamed itself.

Two pharmaceutical CDMOs, AMRI in the US and UK-based Arcinova, have almost simultaneously announced full corporate rebranding exercises. The former has become Curia, which is derived from a Latin word for ‘purposeful assembly’, as of 12 July, while the latter is taking the name Quotient Sciences – Alnwick.